55086-3 |
Cancer treatments in last 14D |
- |
^Patient |
Pt |
- |
|
|
ACTIVE |
Cancer treatments in last 14 days |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.MDS |
|
55086-3 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
Cancer Txs in last 14D; Pan; Panel; Panl; Past; Pnl; Point in time; Random; Survey; SURVEY.MDS; Tx; Txs |
2.68 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
55087-1 |
Number of pressure injuries noted on prior assessment that have completely closed |
- |
^Patient |
Pt |
- |
|
|
DEPRECATED |
Deprecated Number of pressure injuries noted on prior assessment that have completely closed |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.MDS |
|
55087-1 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
No; Num; Pan; Panel; Panl; Pnl; Point in time; Pressure ulcer; Pressure Ulcers; Random; Survey; SURVEY.MDS |
2.7 |
2.27 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
55088-9 |
Pressure injuries - unstageable with suspected deep tissue injury in evolution |
- |
^Patient |
Pt |
- |
|
|
ACTIVE |
Pressure injuries - unstageable with suspected deep tissue injury in evolution |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.MDS |
|
55088-9 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
Pan; Panel; Panl; Pnl; Point in time; Pressure ulcer; Pressure Ulcers; Random; Survey; SURVEY.MDS; Ulcer |
2.68 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
"Pressure ulcers" has been updated to "pressure injuries" according to the new guidelines by the NPUAP and as approved by the Clinical LOINC. |
0 |
55089-7 |
Pressure injuries - unstageable due to coverage of wound bed by slough &or eschar |
- |
^Patient |
Pt |
- |
|
|
ACTIVE |
Pressure injuries - unstageable due to coverage of wound bed by slough/eschar |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.MDS |
|
55089-7 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
Pan; Panel; Panl; Pnl; Point in time; Pressure ulcer; Pressure Ulcers; Random; Survey; SURVEY.MDS |
2.68 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
"Pressure ulcers" has been updated to "pressure injuries" according to the new guidelines by the NPUAP and as approved by the Clinical LOINC. |
0 |
5509-5 |
CD6 |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD6 cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5509-5 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD6 WBC-aCnc |
|
|
|
|
|
Arbitrary concentration; CELL MARKERS; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; T12; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
55090-5 |
Cells.CD3-CD56+/Cells |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD3-CD56+ cells/cells in Blood |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
55090-5 |
|
|
|
|
Observation |
|
|
|
0 |
CD3-CD56+ Cells NFr Bld |
|
|
|
N |
|
Blood; CD3 Cells; CD3+CD56+ Cells; CD3-CD56+ Cells; Cell; CELL MARKERS; Cellularity; Leu19; Leu-19; Leu4; Leu-4; Natural killer cells; NCAM; Neural cell adhesion molecule; NKH1; Number fraction; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; T3; WB; Whole blood |
2.79 |
2.27 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
55091-3 |
Darunavir |
Susc |
Isolate |
Pt |
Ord |
Genotyping |
|
ACTIVE |
Darunavir [Susceptibility] by Genotype method |
|
MIN |
DefinitionDescription |
|
|
|
New drugs added to HIV-1 Antiretroviral Drug Resistance Panel Reported as Sensitive, Low Resistance, High Resistance, Possible Resistance |
|
|
|
|
|
ABXBACT |
|
55091-3 |
|
Genotyping |
|
|
Both |
|
|
|
0 |
Darunavir Islt Genotyp |
|
|
|
N |
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; DRV; Genotype; Genotypic; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Ordinal; Point in time; Prezista; QL; Qual; Qualitative; Random; Screen; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TMC114 |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Corrected Scale from OrdQn to Ord because Genotyping does not produce a quantitative susceptibility result |
0 |
55092-1 |
PDGFRA gene rearrangements |
Arb |
Bld/Tiss |
Pt |
Ord |
Molgen |
|
ACTIVE |
PDGFRA gene rearrangements [Presence] in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.REARRANGE |
|
55092-1 |
|
Molgen |
|
|
Both |
|
|
|
0 |
PDGFRA gene Rear Bld/T Ql |
|
|
|
N |
|
Arbitrary; Blood; CD140A; FIP1L1-PDGFRA; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.REARRANGEMENTS; Ordinal; PCR; PDGFR2; PDGFR-2; platelet-derived growth factor receptor, alpha polypeptide; Point in time; QL; Qual; Qualitative; Random; Rearr; Rearrangement; RHEPDGFRA; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
55093-9 |
Vendor email address |
EmailAddr |
Software |
Pt |
Nom |
|
|
ACTIVE |
Vendor email address Software |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.MDS |
|
55093-9 |
|
|
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
Nominal; Point in time; Random; Survey; SURVEY.MDS |
2.27 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
55094-7 |
Medications |
- |
^Patient |
Pt |
- |
MDSv3 |
|
ACTIVE |
Medications [MDSv3] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.MDS |
|
55094-7 |
|
MDSv3 |
|
|
|
|
|
|
0 |
|
|
|
|
N |
|
MDS version 3; Pan; Panel; Panl; Pnl; Point in time; Random; Survey; SURVEY.MDS |
2.68 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
55095-4 |
Adenovirus |
PrThr |
XXX |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Adenovirus [Presence] in Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
Positive/Negative |
|
|
|
|
|
MICRO |
|
55095-4 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
HAdV Spec Ql Cult |
|
|
|
N |
|
Adeno virus; C&S; Cult; Cultures; HAdV; ID; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
55096-2 |
Nocardia sp |
Prid |
Isolate |
Pt |
Nom |
|
|
ACTIVE |
Nocardia sp identified in Isolate |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
55096-2 |
|
|
|
|
Both |
|
|
|
0 |
Nocardia Islt |
|
|
|
N |
|
ID; Identity or presence; Infectious Disease; InfectiousDisease; Islt; Isol; Microbiology; Nominal; Point in time; Random; species; spp |
2.79 |
2.27 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
55097-0 |
Parainfluenza virus 1 |
PrThr |
XXX |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Parainfluenza virus 1 [Presence] in Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
Positive/Negative |
|
|
|
|
|
MICRO |
|
55097-0 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
HPIV1 Spec Ql Cult |
|
|
|
N |
|
C&S; Cult; Cultures; HPIV; HPIV1; Human respirovirus 1; i; ID; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Ordinal; Other; Para; Parainflu; Parainfluenza type 1; Parainfluenza type I; PI1; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
55098-8 |
Parainfluenza virus 2 |
PrThr |
XXX |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Parainfluenza virus 2 [Presence] in Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
Positive/Negative |
|
|
|
|
|
MICRO |
|
55098-8 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
HPIV2 Spec Ql Cult |
|
|
|
N |
|
C&S; Cult; Cultures; HPIV; HPIV2; Human rubulavirus 2; ID; II; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Ordinal; Other; Para; Parainflu; Parainfluenza type 2; Parainfluenza type II; PI2; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
55099-6 |
Parainfluenza virus 3 |
PrThr |
XXX |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Parainfluenza virus 3 [Presence] in Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
Positive/Negative |
|
|
|
|
|
MICRO |
|
55099-6 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
HPIV3 Spec Ql Cult |
|
|
|
N |
|
C&S; Cult; Cultures; HPIV; HPIV3; Human respirovirus 3; ID; III; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Ordinal; Other; Para; Parainflu; Parainfluenza type 3; Parainfluenza type III; PI3; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
551-2 |
Brucella sp |
Prid |
Bld |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Brucella sp identified in Blood by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
551-2 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Brucella Bld Cult |
|
|
|
|
|
Blood; Bruc; Brucellosis; C&S; Cult; Cultures; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random; Spec; species; spp; WB; Whole blood |
2.79 |
1 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
5510-3 |
CD61 |
ACnc |
WBC |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated CD61 cells/100 cells in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
5510-3 |
|
|
|
|
|
|
|
|
0 |
Deprecated CD61 WBC-aCnc |
|
|
|
|
|
Arbitrary concentration; Beta 3; Beta 3 integrin chain; Beta3; Beta-3 integrin; CD61A; CELL MARKERS; GPIIb/IIIa; Leukocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; WBCs; White blood cells |
2.69 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
55100-2 |
Respiratory syncytial virus |
PrThr |
XXX |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Respiratory syncytial virus [Presence] in Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
Positive/Negative |
|
|
|
|
|
MICRO |
|
55100-2 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
RSV Spec Ql Cult |
|
|
|
N |
|
C&S; Cult; Cultures; HRSV; ID; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; RSV; Screen; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
55101-0 |
Respiratory pathogens panel |
- |
XXX |
Pt |
- |
Organism specific culture |
|
ACTIVE |
Respiratory pathogens panel - Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
Positive/Negative |
|
|
|
|
|
PANEL.MICRO |
|
55101-0 |
|
Organism specific culture |
|
|
Order |
|
|
|
0 |
Respiratory path Pnl Spec Cult |
|
|
|
N |
|
C&S; Cult; Cultures; ID; Infectious Disease; InfectiousDisease; Lung; Microbiology; Misc; Miscellaneous; Other; Pan; PANEL.MICROBIOLOGY; Panl; Pnl; Point in time; Pulmonary; Pulmonology; Random; Resp pathogens; Respiratory; Respiratory bacteria & viruses; Respiratory path Pnl; Respiratory virus panel; Respiratory viruses panel; RVP; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.27 |
|
Panel |
|
|
|
|
|
|
|
|
Changed panel name from "Respiratory virus panel" to "Respiratory pathogens panel" for naming consistency across terms. |
0 |
55102-8 |
Surgical operation note disposition |
Find |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Surgical operation note disposition Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.SURG PROC |
|
55102-8 |
|
|
|
|
|
|
|
|
0 |
Operative note disposition |
|
|
|
N |
|
Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; H+P; H+P.SURGICAL PROCEDURES; Narrative; notes; Operative note; Operative note disposition; P prime; Point in time; Random; Report; Surg; Visit note |
2.63 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
55103-6 |
Surgical operation note estimated blood loss |
Find |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Surgical operation note estimated blood loss Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.SURG PROC |
|
55103-6 |
|
|
|
|
|
|
|
|
0 |
Operative note estimated blood loss |
|
|
|
N |
|
Bld loss; Blood output; Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; H+P; H+P.SURGICAL PROCEDURES; Narrative; notes; Operative note; Operative note estimated blood loss; P prime; Point in time; Random; Report; Surg; Visit note |
2.63 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
55104-4 |
Surgical operation note planned procedure |
Find |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Surgical operation note planned procedure Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.SURG PROC |
|
55104-4 |
|
|
|
|
|
|
|
|
0 |
Operative note planned procedure |
|
|
|
N |
|
Encounter; Evaluation and management; Evaluation and management note; Finding; Findings; H+P; H+P.SURGICAL PROCEDURES; Narrative; notes; Operative note; Operative note planned procedure; P prime; Point in time; Random; Report; Surg; Visit note |
2.63 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
55105-1 |
OTC - Purpose section |
- |
^FDA product label |
- |
Nar |
|
|
ACTIVE |
FDA product label OTC - Purpose section |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOCUMENT.REGULATORY |
|
55105-1 |
|
|
|
|
|
|
|
|
0 |
FDA label OTC - Purpose |
|
|
|
N |
|
DOCUMENT.REGULATORY; FDA label; Narrative; Over-the-counter; Report |
2.34 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
55106-9 |
OTC - Active ingredient section |
- |
^FDA product label |
- |
Nar |
|
|
ACTIVE |
FDA product label OTC - Active ingredient section |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOCUMENT.REGULATORY |
|
55106-9 |
|
|
|
|
|
|
|
|
0 |
FDA label OTC - Active ingredient |
|
|
|
N |
|
DOCUMENT.REGULATORY; FDA label; Narrative; Over-the-counter; Report |
2.34 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |
55107-7 |
Addendum |
Find |
^Patient |
Pt |
Doc |
|
|
ACTIVE |
Addendum Document |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOC.MISC |
|
55107-7 |
|
|
|
|
Both |
|
|
|
0 |
Addendum Doc |
|
|
|
N |
|
DOC.MISC; Document; Finding; Findings; MISC; Point in time; Random |
2.73 |
2.27 |
|
|
|
|
|
|
|
|
|
|
|
0 |